While no standardized diagnostic criteria have been established, the presence of positive ANA and anti-histone antibodies, along with SLE-like symptoms, particularly arthralgia, arthritis, or myalgia, in patients receiving known lupus-inducing medications such as hydralazine, is often sufficient to support a diagnosis of DIL. The gene discussed is BTG3; the disease is systemic lupus erythematosus.